Abstract
Executive Summary
Cancer immunotherapy offers an attractive therapeutic addition, delivering
treatment of high specificity, low toxicity and prolonged activity. In this
Drug Pipeline Update BioSeeker brings together the fields of antibodies,
vaccines, and immunostimulators in oncology drug development into one source.
There are today more than 290 immunotherapy drugs in active development for
the treatment of cancer, from early preclinical to marketed drugs. In
addition, the accumulated number of ceased drugs over the last three years
amount to another 159 drugs. Immunotherapy in Oncology: Drug Pipeline Update
lists all drugs and gives you a progress analysis on each one of them.
Identified drugs are linked to 84 different targets. These targets are further
categorized on the CD-ROM by 37 classifications of molecular function and with
pathway referals to BioCarta, KEGG and NetPath. Read more below on how the
Immunotherapy in Oncology: Drug Pipeline Update is organized.
How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug
development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc.
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
- Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/out licensing strategy work
- Fast and easy way of tracking drugs using search engines; just one click
from inside the application and you may search the World Wide Web and PubMed
for any drug.
Drug Pipeline Update is delivered to you as a CD-ROM application, which
requires no installation on your computer.
| 
View Cart
